IgD multiple myeloma: Clinical, biological features and prognostic value of the serum free light chain assay

Kyle, 2004, Multiple myeloma, N Engl J Med, 351, 1860, 10.1056/NEJMra041875 Rajkumar, 2005, Multiple myeloma: diagnosis and treatment, Mayo Clin Proc, 80, 1371, 10.4065/80.10.1371 Bladé, 1994, Immunoglobulin D multiple myeloma presenting features response to therapy, and survival in a series of 53 cases, J Clin Oncol, 12, 2398, 10.1200/JCO.1994.12.11.2398 Fine, 1969, Deux cas de myelome avec immunoglobuline IgD a character monoclonal, Rev Fr Etudes Clin Biol, 14, 1018 Fahey, 1968, Plasma cell myeloma with D-myeloma protein (IgD myeloma), Am J Med, 45, 373, 10.1016/0002-9343(68)90071-5 Jancelewicz, 1975, IgD multiple myeloma. Review of 133 cases, Arch Intern Med, 135, 87, 10.1001/archinte.1975.00330010089012 Gertz, 2012, Immunoglobulin D amyloidosis: a distinct entity, Blood, 119, 44, 10.1182/blood-2011-06-358895 Bradwell, 2001, Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine, Clin Chem, 47, 673, 10.1093/clinchem/47.4.673 Bradwell, 2002, Serum free light chain immunoassays and their clinical application, Clin Appl Immunol Rev, 3, 17, 10.1016/S1529-1049(02)00064-8 Dispenzieri, 2009, International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders, Leukemia, 23, 215, 10.1038/leu.2008.307 Keren, 1999, Guidelines for clinical and laboratory evaluation patients with monoclonal gammopathies, Arch Pathol Lab Med, 123, 106, 10.5858/1999-123-0106-GFCALE Katzmann, 2002, Serum reference intervals and diagnostic ranges for free kappa and free lambda immunogloblin light chains, Clin Chem, 48, 1437, 10.1093/clinchem/48.9.1437 Hutchison, 2008, Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure, BMC Nephrol, 9, 11, 10.1186/1471-2369-9-11 Snozek, 2008, Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system, Leukemia, 22, 1933, 10.1038/leu.2008.171 Durie, 1975, A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features response to treatment, and survival, Cancer, 36, 842, 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U Pisani, 2012, IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy, J Exp Clin Cancer Res, 31, 17, 10.1186/1756-9966-31-17 Wechalekar, 2005, IgD multiple myeloma–a clinical profile and outcome with chemotherapy and autologous stem cell transplantation, Ann Hematol, 84, 115, 10.1007/s00277-004-0944-x Friman, 1970, IgD myeloma associated with multiple extramedullary amyloid containing tumors and amyloid casts in the renal tubules, Ann Clin Res, 2, 161 Shimamoto, 1991, A new risk grouping for IgD myeloma based on analysis of 165 Japanese patients, Eur J Haematol, 47, 262, 10.1111/j.1600-0609.1991.tb01569.x Pruzanski, 1970, IgD plasma cell neoplasia: clinical manifestations and characteristic features, Can Med Assoc J, 102, 1061 LeQuellec, 1989, Immunoglobulin D multiple myeloma. A retrospective study in the Languedoc region, Presse Med, 18, 1110 Fibbe, 1984, Prognostic factors in IgD myeloma: a study of 21 cases, Scand J Haematol, 33, 471, 10.1111/j.1600-0609.1984.tb00727.x Alcalay, 1975, Le myélome à IgD, à propos d’un cas, Sem Hop, 51, 1227 Kuliszkiewicz-Janus, 2005, Immunoglobulin D myeloma–Problems with diagnosing and staging (own experience and literature review), Leuk Lymphoma, 46, 1029, 10.1080/00268970500096442 Greipp, 2005, International staging system for multiple myeloma, J Clin Oncol, 23, 3412, 10.1200/JCO.2005.04.242 Wechalekar, 2005, IgD multiple myeloma–a clinical profile and outcome with chemotherapy and autologous stem cell transplantation, Ann Hematol, 84, 115, 10.1007/s00277-004-0944-x Kyrtsonis, 2007, Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma, Br J Haematol, 137, 240, 10.1111/j.1365-2141.2007.06561.x Mead, 2004, Serum free light chains for monitoring multiple myeloma, Br J Haematol, 126, 348, 10.1111/j.1365-2141.2004.05045.x Bradwell, 2003, Serum test for assessment of patients with Bence Jones myeloma, Lancet, 361, 489, 10.1016/S0140-6736(03)12457-9 van Rhee, 2007, High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis, Blood, 110, 827, 10.1182/blood-2007-01-067728